"I think you should know from here, its price decay." Not seeing that today at least. Seems pretty strong on a horrible market day. JMO
...use a SELL STOP. The MM see's your sell point and can now judge how far to drop the stock to take your shares and clear a bunch of Sell Stop from you rookies...you lock in your losses...so now the MM turning around and selling your shares higher. Don't play their game. if you must, have a "mental Sell Stop ". You are giving the MM the advantage using a Sell Stop.
WoW!!! What a come back. What's next? Are you going to give me The Sticks and Stones or the I'm Rubber and You're Glue line?
semanresu says....."How does that dunce cap feel? A little tight around the ears? LoL"........while looking in the mirror.
Dilution of what ? You do understand EXEL is NOT about earnings as of yet.......don't you ?
Go back to sleep.
Just Reminding Unsuspecting Longs of the Dilution They would be buying...
cbdthelp You should start up a newspaper company, suggestion for a name for the company. The Old News .
You could compete with The New York Daily News.
I can see you are an ideal customer for the driverless car, you're always asleep at the wheel.
A handsome gain for Cowan. PPS may be under pressure a little more today.
The offering is expected to close on or about July 29, 2015.
" Z/C is the better BRAF/MEK combo and will take away D/T's share pretty quick. We will have to see how the Nivo/Ipi situation works out. Certainly D/T will capture the 2nd line BRAF+ spot and maybe some of the frontline also. If I had melanoma I would go straight to Nivo/Ipi hoping for a durable response."
My wife has NSCLC and is BRAF+. Currently on D/T. Will have a scan in a few weeks which will be the first feedback. The melanoma D/T trial had high response rate (60s) so they started a trial for NSCLC BRAF+ as well. Also there a high response rate, trial was halted to be reopened a few months back again but for treatment naive patients only. D/T may well become a first line treatment. We are hopeful for a good response but side effects are a challenge. Z was an option but the feedback we got was that D/T was the better one. Durable response is an issue. So if push come to shove may have to go to an immunotherapy combo where response is more variable (not so high as D/T) depending on degree of expression but likely more durable.